Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
Patents for C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
10/2005
10/27/2005WO2005100314A1 Crystalline polymorph of bazedoxifene acetate
10/27/2005WO2005100308A1 Thio-substituted biaryl-methanesulfinyl derivatives
10/27/2005WO2005100305A1 Androgen modulators
10/27/2005WO2005100298A1 Cetp inhibitors
10/27/2005WO2005099709A2 Bicyclic heterocycles useful as serine protease inhibitors
10/27/2005WO2005061483A3 Modulators of peripheral 5-ht receptors
10/27/2005WO2005034848A3 Inhibitors of cathepsin s
10/27/2005WO2004089366A8 Bicyclic compounds as nr2b receptor antagonists
10/27/2005WO2004048330A8 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
10/27/2005US20050240027 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
10/27/2005US20050240023 Cathepsin cysteine protease inhibitors
10/27/2005US20050239898 Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
10/27/2005US20050239841 New compounds
10/27/2005US20050239839 Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
10/27/2005US20050239787 Novel maxi-k channel blockers, methods of use and process for making the same
10/27/2005US20050239107 Trapped photochromes and thermochromes and uses for chromogenic detection, including detection of airborne contaminants
10/27/2005US20050238992 Exposure latitude and line-edge roughness
10/27/2005US20050236980 Charge transport compositions and electronic devices made with such compounds
10/27/2005CA2563291A1 4-cyano-phenoxy-alkyl carboxyl derivatives as androgen modulators
10/27/2005CA2563225A1 Process for preparing pyridazinone compounds
10/27/2005CA2563010A1 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
10/27/2005CA2562843A1 Process for the preparation of perindopril
10/27/2005CA2562401A1 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
10/27/2005CA2562082A1 Cetp inhibitors for the treatment and prevention of atherosclerosis
10/27/2005CA2561296A1 Crystalline polymorph of bazedoxifene acetate
10/27/2005CA2561010A1 Crystalline polymorph of bazedoxifene acetate
10/27/2005CA2561004A1 Bazedoxifene ascorbate as selective estrogen receptor modulator
10/26/2005EP1589016A1 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1587877A1 Beta-isoindigo coloring agent
10/26/2005EP1587815A2 Compounds and processes for single-pot attachment of a label to nucleic acid
10/26/2005EP1587798A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
10/26/2005EP1587788A1 2,7-substituted indoles and their use as 5-ht6 modulators
10/26/2005EP1587787A1 Viral polymerase inhibitors
10/26/2005EP1587786A1 2.4-DIHALOGEN-6-(C sb 2 /sb -C sb 3 /sb -ALKYL)-PHENYL SUBSTITUTED TETRAMIC ACID DERIVATIVES
10/26/2005EP1587585A1 Acylsulfonamide compounds as inhibitors of rna-dependent rna (viral) polymerases
10/26/2005EP1587474A2 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
10/26/2005EP1587473A2 Thiosemicarbazones as anti-virals and immunopotentiators
10/26/2005EP1427408A4 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE)
10/26/2005EP1212081B1 Use of ace inhibitors in the prevention of congestive heart failure
10/26/2005EP1183229B1 Glucagon antagonists/inverse agonists
10/26/2005CN1688586A Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
10/26/2005CN1688544A Fluoro and sulphonylamino containing 3, 6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
10/26/2005CN1688541A Novel compounds comprising a thiocarbonyl-sulfanyl group, which can be used for the radical synthesis of alpha-perfluoroalkylamines
10/26/2005CN1688527A Fused benzene derivative and use
10/26/2005CN1687034A Method for synthesizing 4-phthalimide methyl phthalonitrile
10/26/2005CN1687033A Medication for anti virus of respiratory tract and application
10/26/2005CN1687032A Synthesized intermediate compound of Rosuvastain, preparation method and application
10/26/2005CN1224697C Process for preparation of amino alcohols and derivatives thereof
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/25/2005US6958348 Side effect reduction
10/25/2005US6958338 E.g., 5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-indole; partial agonists or antagonist at the dopamine D4 receptors; psychoses, schizophrenia, cognition activators; attention deficit disorder; dyskinesia; side effects reduction
10/25/2005CA2331053C Compositions and methods for treating conditions responsive to estrogen
10/25/2005CA2331009C Compositions and methods of treatment for conditions responsive to testosterone elevation
10/25/2005CA2170223C [3-amino]-tetrahydrocarbazole-propanoic acid esters
10/25/2005CA2110454C 1,5,7-trisubstituted indoline compounds for the treatment of dysuria
10/20/2005WO2005097745A1 Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives
10/20/2005WO2005097744A1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity and the monoamine reuptake for the treatment of vasomotor symptoms (vms)
10/20/2005WO2005097713A1 Fluoridation method
10/20/2005WO2005097107A2 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005WO2005085236A3 Caspase inhibitors and uses thereof
10/20/2005WO2005082851A3 Charge transport compounds and electronic devices made with such compounds
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2005009370A3 Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
10/20/2005WO2004113292A3 Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
10/20/2005US20050234244 Synthesis of COX-2 and FAAH inhibitors
10/20/2005US20050234242 Coupling of a 2-haloindole with an (hetero)aryl zinc intermediate in the presence of a palladium or nickel-containing catalyst, phosphine ligand and a solvent selected from tetrahydrofuran, dimethylformamide and N-methylpyrrolidone; by-product inhibition; hepatitis C virus polymerase inhibitors
10/20/2005US20050234239 Method of forming a carbon-carbon or carbon-heteroatom linkage
10/20/2005US20050234236 Process for preparing pyridazinone compounds
10/20/2005US20050234120 For example, 5-acetyl-3-{[4-(diethylaminomethyl)-phenylamino]-phenyl-methylidene}-2-indolinone; for treatment of diabetes mellitus, diabetes associated disorders such as diabetic neuropathy, degenerative neurological diseases such as Alzheimer's disease, stroke, neurotraumatic injuries, bipolar disorders
10/20/2005US20050234065 Dipeptidyl peptidase-IV inhibitors
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234058 Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
10/20/2005US20050234030 Modulators of CRTH2, COX-2 and FAAH
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050233979 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
10/20/2005CA2562399A1 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005CA2560967A1 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine (ne) and the serotonine (5-ht) activity andthe monoamine reuptake for the treatment of vasomotor symptoms (vms)
10/19/2005EP1586559A1 Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives
10/19/2005EP1585744A1 Process for making ondansetron and intermediates thereof
10/19/2005EP1585731A2 Histamine h3 receptor antagonists, preparaton and therapeutic uses
10/19/2005EP1585728A1 Imino acid derivatives for use as inhibitors of matrix metalloproteinases
10/19/2005EP1585727A1 Indoles useful in the treatment of androgen-receptor related diseases
10/19/2005EP1585726A1 Fused heterocyclic derivatives as ppar modulators
10/19/2005EP1585511A2 Asthma and allergic inflammation modulators
10/19/2005EP1463714A4 Vanilloid receptor ligands and their use in treatments
10/19/2005EP1311263B1 Fused pyrrolocarbazoles against inflammation
10/19/2005CN1684944A Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
10/19/2005CN1684681A Bicifadine formulation
10/19/2005CN1224297C Complexes of form L2MX as phosphorescent dopants for organic LEDS
10/18/2005US6956054 Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel
10/18/2005US6955869 Organophotoreceptor with a charge transport material having two azine groups
10/18/2005US6955856 improved emmission/efficiency and thermal/crystal stability
10/18/2005CA2295063C Indole compounds as anti-inflammatory/analgesic agents
10/18/2005CA2294171C N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
10/18/2005CA2240728C Kappa agonist compounds and pharmaceutical formulations thereof
10/13/2005WO2005095341A1 Nitrogen-containing heterocyclic compound
10/13/2005WO2005095338A1 Alkoxyphenylpropanoic acid derivatives
10/13/2005WO2005095327A1 Aniline derivatives
10/13/2005WO2005094897A2 Pegylated ion channel modulating compounds
1 ... 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 ... 458